Pharmacostatistical Modeling and Simulation of Randomized Clinical PrEP Trials
Location(s): United States
Research related to pre-exposure prophylaxis (PrEP) against the human immunodeficiency (HIV) virus, which causes AIDS.This project assesses the pre-exposure prophylaxis antiretroviral agent tenofovir in individuals who do not have HIV/AIDS but may be at risk of contracting it.
A key factor in the success of preventing HIV contraction is the levels of tenofovir in the body. This project will use data acquired from multiple clinical trials to develop pharmacokinetic models that describe the relationship between administration of tenofovir and actual levels of the drug in the blood, specific blood cells that become infected with HIV and other tissues.
The resulting models will be used to create a clinical decision tool.